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Sir,
The term inflammatory breast cancer (IBC) was first used by Lee and
Tannenbaum in 1924 (Lee and Tannenbaum, 1924). This uncommon
form of breast cancer accounts for 2.5% of all breast cancer in the United
States of America (Robertson et al, 2010), there are no published figures
for incidence in the United Kingdom. IBC is widely acknowledged as an
extremely aggressive form of locally advanced breast cancer with a very
poor prognosis (Hance et al, 2005). In the past, progress of research into
this condition has been limited by the lack of consistent, definitive and
well-documented diagnostic criteria. The generation of evidence-based
guidelines for the management of IBC is compromised by the paucity of
data that is often of variable quality (e.g., due to small sample sizes).
There have been only a few clinical trials designed exclusively for IBC
with very few of these being randomised (Dawood and Cristofanilli,
2011). Data have primarily been comprised of small- to modest-sized
cohorts of patients, often from trials where inflammatory cancers were
included but not the primary target population for the trial. Statistical
power to examine IBC cohorts in isolation within these trials is inevitably
limited.
Recently, an International panel published a consensus statement for
standardised diagnosis and management of IBC (Dawood et al, 2011). To
date no effort has been made to co-ordinate or standardise UK practice
and research endeavours regarding IBC.
The aims of the UK IBC working group are to establish a National
mechanism for conducting research into IBC. It has thus far explored
mechanisms for central collection of clinical, pathological and radi-
ological data on diagnostic parameters, treatment and outcomes linked to
tumour material that could serve as a clinical research resource. The
initial outcome was to provide practical guidelines to encourage
consistent definition, uniform collection of diagnostic information and
standardisation of treatment approaches.
The International consensus statement remains an important
contemporary blueprint for IBC management and the UK working
group endorses it. The current paper seeks to provide a UK perspective
on the diagnostic criteria, required documentation and commonly
used treatments of IBC to give momentum and generate research interest
into this disease in the United Kingdom. The UK group will separately
identify key elements required to establish a collaborative research
platform to enable the epidemiology and biology of this condition to be
better understood and for specific research to be conducted aimed at
improving outcomes for women afflicted by this challenging condition.
DEFINITION OF IBC
The first diagnostic criteria for IBC were published in 1956 by Haagensen
(Haagensen, 1956). These criteria are the basis of the definition of IBC set
forth by the American Joint Committee on Cancer (AJCC) as ‘a
clinicopathological entity characterised by diffuse erythema and oedema
of the breast, often without an underlying palpable mass’ (AJCC, 2002).
The diagnosis of IBC remains a clinical diagnosis with pathological
confirmation of invasive disease with no specific additional pathological
criteria and has therefore been open to subjectivity. The standardisation
of diagnostic criteria is essential and will help minimise such subjectivity.
Collection of good data sets in relationship to each case is also essential as
is an accurate description of the individual features contributing to the
diagnosis of each case of IBC.
CLINICAL PARAMETERS
One key diagnostic difficulty is the separation of the recognised feature of
an aggressive rapidly appearing and progressive condition and a more
indolent but long neglected locally advanced primary breast cancer. This
has resulted in the requirement of a short history of less than 6 months as
a diagnostic criterion. Although this is an arbitrary time cutoff, it will
clearly separate the majority of slowly evolving locally advanced cancers.
PATHOLOGICAL CRITERIA
Importantly, IBC has no specific histological appearance and as such is
not a recognised morphological subtype of invasive breast cancer. The
current WHO definition (Lakhani et al, 2012) recognises that the
diagnosis is based on clinical findings but emphasises that the clinical
picture is a consequence of dermal lymphatic involvement and
embolisation. The underlying invasive breast cancer is usually high
grade and of no special type. There is evidence that tumours associated
with an inflammatory clinical presentation are highly angiogenic,
lymphangiogenic and vasculogenic (Vermeulen et al, 2010).
It is essential to acquire a tissue diagnosis of carcinoma, as infection,
some inflammatory conditions and other tumours (notably some
sarcomas) can mimic the inflammatory carcinoma clinical picture.
Dermal lymphovascular tumour emboli present in a skin punch biopsy is
a typical but not specific feature. Although multiple dermal punch
biopsies are not required for a diagnosis, taking such biopsies can aid the
diagnosis of IBC and provide a subclasification.
RADIOLOGICAL FEATURES
Although routine breast radiological investigations are recommended as
part of staging work-up, the data are currently not sufficient to define any
radiological signs specific for IBC. Radiological findings do not feature as
part of the diagnostic criteria. Nonetheless, with full field digital
mammography, skin and trabecular thickening are seen far more
frequently than with conventional film/screen mammography, often
with associated distortion and diffuse increase in breast density—a
constellation of findings that is highly suggestive of the diagnosis
(Gunhan-Bilgen et al, 2002; Le-Petross et al, 2008). High-resolution
ultrasound demonstrates a focal abnormality in over 90% of cases,
facilitating targeted biopsy (Gunhan-Bilgen et al, 2002; Le-Petross et al,
2008). Key diagnostic features on breast MRI are diffuse breast and
prepectoral oedema, diffuse skin thickening and enhancement (present in
over 90%, in contrast to neglected LABC) and either non-mass
enhancement or multiple small masses throughout the breast
(Le-Petross et al, 2011; Uematsu, 2012).
TREATMENT
Primary systemic therapy is the recommended first-line approach to
treatment of IBC. A surgical opinion regarding feasibility of primary
resection should be obtained prior to systemic therapy, and operable or
successfully downstaged cancers should all be resected following primary
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systemic therapy. Post-operative radiation therapy is almost always
indicated (Yamauchi et al, 2012).
RECOMMENDATIONS FOR PROGRESS
We propose a series of recommendations for the diagnosis and
management of IBC, which are summarised in Tables 1 and 2. These
recommendations have many aspects in common with the International
recommendations, but differ in certain respects. We discuss below the
rationale for these differences.
Diagnostic criteria. The International guidelines and AJCC
guidelines 7th edition state that erythema and oedema should be
present in at least one-third of the breast. We have not specified
criteria for the proportion of breast involvement or size criteria for
erythema (or oedema), as this was considered too subjective to
include as a useful specific criterion. It is particularly difficult to
assess erythema inpigmented skin. We have instead recommended
that the external appearance is documented by clinical photo-
graphy, thus capturing much more detail than a narrative
description alone.
Staging and response assessment. We have recommended a
combination of mammography and ultrasound as minimum require-
ments for radiological imaging of the breast. MRI is also recom-
mended, as this is the most accurate technique for characterisation and
diagnosis of the primary lesion (Yang et al, 2008; Le-Petross et al,
2011). There are specific features that aid the differentiation from
LABC (Le-Petross et al, 2011; Uematsu, 2012). In addition, it is
accepted that in comparison with conventional imaging, MRI is the
most accurate way of assessing both interim and final responses to
treatment (Dall et al, 2011), which can help to guide therapy (for e.g.,
where breast conservation may be a possibility or to demonstrate
persistent involvement of the chest wall musculature).
The presence of metastatic disease is common in women presenting
with IBC, and staging clearly provides important information for
prognosis and management and CT scanning is widely available and
recommended as the primary staging modality. Bone scintigraphy is now
recognised as adding little additional value over CT staging and is not
recommended as a routine staging investigation in keeping with current
UK practice. By contrast, PET-CT is a very effective investigation for
identification of asymptomatic metastasis (Groheux et al, 2013) and
where available, its use is encouraged.
Management. We have recommended concurrent use of primary
cytotoxic therapy for HER-2-negative cancers and a combination
of cytotoxic and anti-HER-2-based therapy for tumours
overexpressing HER-2. There is now good evidence that pCR
rates in HER-2-positive cancers can be significantly enhanced with
chemotherapy and dual-targeted anti-HER-2 therapy using
chemotherapy and trastuzumab with either pertuzumab or
Lapatinib (Rea et al, 2013). Where dual-targeted therapy is
available, we would endorse its use in treatment of IBC.
Breast surgery. Following neoadjuvant chemotherapy, excellent
clinical responses may be achieved including a pathological
complete response. In the absence of any data to suggest breast-
conserving surgery (BCS) with clear margins is any less safe than in
patients with non-IBC, there is no justification for the mandatory
requirement for maintaining the convention of recommending
mastectomy in all patients with IBC. Thus, attempted breast
conservation after adequate downstaging can be considered based
on multidisciplinary review of pre- and post-treatment clinical,
radiological and pathological features.
Axillary management. There is no published evidence that
suggests patients with IBC treated with neoadjuvant chemotherapy
should have their axilla staged or treated any differently to any
other patients with invasive breast cancer undergoing neoadjuvant
chemotherapy.
Radiotherapy. Adjuvant radiotherapy is the recognised standard
of care following surgery for IBC and should only be omitted
where there are clear contraindications. Supraclavicular radio-
therapy is therefore recommended in all patients with documented
or suspected axillary node involvement at diagnosis. Internal
mammary chain radiation should be considered if there is any
radiological suspicion of internal mammary node involvement, but
the evidence for internal mammary node involvement as routine
practice for all women with IBC and axillary node involvement is
not considered strong enough for a recommendation for this to be
applied in all cases.
Endocrine therapy. We have included a recommendation that all
hormone receptor-positive patients receive post-operative adjuvant
endocrine therapy as would be standard therapy after surgery for
all early breast cancers.
Ultimately, by establishing clear national guidelines in IBC we aim to
develop future IBC-specific clinical trials and foster long-term clinical
and academic collaborative projects with international partners.
A mechanism for central registration of IBC would supply essential
data to progress the study of this disease. Associated tissue collections will
allow application of emerging new ’-omics’ and next-generation
sequencing technologies to help uncover more about the biology of
IBC, potentially leading to new strategies to improve patient outcomes.
Table 1. UK recommendations for the diagnosis of IBC
Diagnosis Diagnostic procedures Imaging and staging Pathology
| Rapid and progressive onset of breast
erythema or peau d’orange ± underlying
mass with maximum symptomatic
duration of 6 months
| Histopathological or cytological
confirmation of breast cancer on
perioperative biopsy
| Duration and nature of symptoms
| Description of breast appearance
and physical examination
including proportion of breast
involved by erythema
| Degree of extension beyond the
breast if present
| Size and location of any breast
mass and presence of palpable
axillary and supraclavicular fossa
nodes
| Presence of any symptoms or
signs of metastatic cancer.
| A clear statement that the
condition fulfils the diagnostic and
is considered an inflammatory
breast cancer
| Bilateral diagnostic mammography with ultrasound
of the breast and axilla and image-guided biopsy of
suspicious lymph nodes as well as of any focal
ultrasonographic abnormality in the breast
| Clinical photographs of the breast at diagnosis and if
there is any interval progression immediately before
commencing systemic therapy
| MRI in instances where breast parenchymal lesions
are not detected by mammography or breast
ultrasound
| Baseline and subsequent MRI to monitor response to
therapy
| Whole-body staging either with contrast enhanced
CT or PET/CT
| Biopsy to confirm
invasive carcinoma
| Measure of hormone
receptor expression and
HER-2 status




Abbreviations: CT¼ computed tomography; IBC¼ inflammatory breast cancer; PET¼positron emission tomography.
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| In selected cases responding well to
primary systemic therapy, a breast
conservation approach may be
considered
| Immediate reconstruction is not
recommended. Delayed breast
reconstruction is an appropriate option
following mastectomy
| Axillary clearance recommended for
patients with histologically (or
cytologically) proven lymph node
involvement identified by fine-needle
aspiration core biopsy or sentinel
lymph node biopsy
| Assess fitness to receive primary
systemic chemotherapy (a full-dose
anthracycline- and taxane-containing
chemotherapy regimen such as
sequential docetaxel-FEC)
| Anti-HER2 therapy in HER-2-positive
IBC should be administered
concurrently with chemotherapy with
co-administration of anthracycline and
anti-HER2 therapy considered in
patients with no cardiac risk factors
| Assessment of response to primary
systemic chemotherapy should include
a combination of physical examination
and radiological assessment. MRI is







| Post mastectomy, chest wall
radiotherapy is currently
recommended irrespective of
response to systemic therapy
| Supraclavicular fossa radiotherapy
should be given where there is clinical
pathological or radiological
documentation, or suspected axillary
node involvement according standard
treatment protocols
Abbreviations: IBC¼ inflammatory breast cancer; MDT¼Multi-Disciplinary Team; MRI¼magnetic resonance imaging.
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